Immune response to two different dosing schedules of the anthrax vaccine precipitated (AVP) vaccine

Vaccine

Volumn 25, Issue 32, 2007, Pages 6089-6097

  Hepburn, Matthew J ^a   Hugh Dyson, E ^a   Simpson, Andrew J H ^a,b   Brenneman, Karen E ^c   Bailey, Nicola ^a   Wilkinson, Lucy ^a   Hornby, Rebecca ^a   Mateczun, Alfred J ^c   Bell, Matthew G ^c   Baillie, Leslie W J ^c,d  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c NAVAL MEDICAL RESEARCH CENTER   (United States)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Anthrax vaccine precipitated (AVP); Anti protective antigen antibodies; Immune response

Indexed keywords

ANTHRAX VACCINE; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; CELL SURFACE MARKER; GAMMA INTERFERON;

ANTHRAX; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; LETHAL GENE; MALE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL; SEROLOGY; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT RESPONSE; UNITED KINGDOM; VACCINATION; VIRUS NEUTRALIZATION;

ADULT; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; PRECIPITATION;

EID: 34447525273     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.05.018     Document Type: Article

References (23)

1. Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Friedlander A.M., et al. Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 281 (1999) 1735-1745
2. Jernigan D.B., Raghunathan P.L., Bell B.P., Brechner R., Bresnitz E.A., Butler J.C., et al. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 8 (2002) 1019-1028
3. Inglesby T.V., O'Toole T., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287 (2002) 2236-2252
4. Collier R.J., and Young J.A. Anthrax toxin. Annu Rev Cell Dev Biol 19 (2003) 45-70
5. Little S.F., Ivins B.E., Fellows P.F., and Friedlander A.M. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun 65 (1997) 5171-5175
6. Pitt M.L., Little S., Ivins B.E., Fellows P., Boles J., Barth J., et al. In vitro correlate of immunity in an animal model of inhalational anthrax. J Appl Microbiol 87 (1999) 304
7. Pitt M.L., Little S.F., Ivins B.E., Fellows P., Barth J., Hewetson J., et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19 (2001) 4768-4773
8. Reuveny S., White M.D., Adar Y.Y., Kafri Y., Altboum Z., Gozes Y., et al. Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun 69 (2001) 2888-2893
9. Welkos S.L., and Friedlander A.M. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb Pathog 5 (1988) 127-139
10. Baillie L., Townend T., Walker N., Eriksson U., and Williamson D. Characterization of the human immune response to the UK anthrax vaccine. FEMS Immunol Med Microbiol 42 (2004) 267-270
11. Friedlander A.M., Pittman P.R., and Parker G.W. Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAMA 282 (1999) 2104-2106
12. Pittman P.R., Mangiafico J.A., Rossi C.A., Cannon T.L., Gibbs P.H., Parker G.W., et al. Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans. Vaccine 19 (2000) 213-216
13. Pittman P.R., Kim-Ahn G., Pifat D.Y., Coonan K., Gibbs P., Little S., et al. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 20 (2002) 1412-1420
14. Semenova V.A., Steward-Clark E., Stamey K.L., Taylor Jr. T.H., Schmidt D.S., Martin S.K., et al. Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum. Clin Diagn Lab Immunol 11 (2004) 919-923
15. Quinn C.P., Semenova V.A., Elie C.M., Romero-Steiner S., Greene C., Li H., et al. Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg Infect Dis 8 (2002) 1103-1110
16. Welkos S., Little S., Friedlander A., Fritz D., and Fellows P. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147 (2001) 1677-1685
17. Quinn C.P., Dull P.M., Semenova V., Li H., Crotty S., Taylor T.H., et al. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J Infect Dis 190 (2004) 1228-1236
18. Ferrari M.E., Hermanson G., and Rolland A. Development of anthrax DNA vaccines. Curr Opin Mol Ther 6 (2004) 506-512
19. Galloway D., Liner A., Legutki J., Mateczun A., Barnewall R., and Estep J. Genetic immunization against anthrax. Vaccine 22 (2004) 1604-1608
20. Galloway D.R., and Baillie L. DNA vaccines against anthrax. Expert Opin Biol Ther 4 (2004) 1661-1667
21. Grunow R., Porsch-Ozcurumez M., Splettstoesser W., Buckendahl A., Hahn U., Beyer W., et al. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine. Vaccine 25 (2007) 3679-3683 [Epub doi:10.1016/j.vaccine.2007.01.056]
22. Marcus H., Danieli R., Epstein E., Velan B., Shafferman A., and Reuveny S. Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine. Infect Immun 72 (2004) 3471-3477
23. Shlyakhov E., Rubinstein E., and Novikov I. Anthrax post-vaccinal cell-mediated immunity in humans: kinetics pattern. Vaccine 15 (1997) 631-636